UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 115

Sortiert nach

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Journal of clinical oncology, 2019-03, Vol.37 (7), p.537-546

2019

Volltextzugriff (PDF)

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2020-05, Vol.38 (14), p.1505-1517

2020

Volltextzugriff (PDF)

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Journal of clinical oncology, 2020-07, Vol.38 (21), p.2369-2379

2020

Volltextzugriff (PDF)

Small cell lung cancer: will recent progress lead to improved outcomes?

Clinical cancer research, 2015-05, Vol.21 (10), p.2244-2255

2015

Volltextzugriff (PDF)

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

Journal of clinical oncology, 2015-12, Vol.33 (34), p.4106-4111

2015

Volltextzugriff (PDF)

Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

Journal of clinical oncology, 2011-05, Vol.29 (15), p.2066-2070

2011

Volltextzugriff (PDF)

Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis

Lung cancer (Amsterdam, Netherlands), 2023-02, Vol.176, p.132-139

2023

Volltextzugriff (PDF)

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling

Molecular cancer therapeutics, 2012-02, Vol.11 (2), p.485-491

2012

Volltextzugriff (PDF)

First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment

Immunotherapy, 2019-07, Vol.11 (10), p.889-901

2019

Volltextzugriff (PDF)

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

Frontiers in oncology, 2022-03, Vol.12, p.834761-834761

2022

Volltextzugriff (PDF)

Reply to F. Liang

Journal of clinical oncology, 2019-01, Vol.37 (3), p.259-259

2019

Volltextzugriff (PDF)

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

Clinical cancer research, 2012-02, Vol.18 (4), p.1138-1145

2012

Volltextzugriff (PDF)

Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma

European journal of cancer (1990), 2024-08, Vol.207, p.114146, Article 114146

2024

Volltextzugriff (PDF)

Kidney Tubular Toxicity of Maintenance Pemetrexed Therapy

American journal of kidney diseases, 2011-11, Vol.58 (5), p.817-820

2011

Volltextzugriff (PDF)

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

Clinical cancer research, 2011-04, Vol.17 (8), p.2521-2527

2011

Volltextzugriff (PDF)

Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer

Frontiers in oncology, 2024-01, Vol.13, p.1225820-1225820

2024

Volltextzugriff (PDF)

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

Journal for immunotherapy of cancer, 2023-03, Vol.11 (3), p.e006398

2023

Volltextzugriff (PDF)

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

Cancer, 2012-01, Vol.118 (2), p.493-499

2012

Volltextzugriff (PDF)

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

Cancers, 2022-02, Vol.14 (4), p.1041

2022

Volltextzugriff (PDF)

Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation

Radiotherapy and oncology, 2017-10, Vol.125 (1), p.130-135

2017

Volltextzugriff (PDF)

Bronchial and Thymic Carcinoid Tumors

Hematology/oncology clinics of North America, 2016-02, Vol.30 (1), p.83-102

2016

Volltextzugriff (PDF)

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

JTO clinical and research reports, 2023-01, Vol.4 (1), p.100431-100431, Article 100431

2023

Volltextzugriff (PDF)

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Journal of clinical oncology, 2021-07, Vol.39 (21), p.2339-2349

2021

Volltextzugriff (PDF)

1 – 25 von 115

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(109)
Mit Volltextzugriff
(107)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(58)
Science & Technology
(58)
Humans
(50)
Oncology
(50)
Female
(31)
Male
(31)
Lung Neoplasms - Drug Therapy
(27)
Middle Aged
(26)
Aged
(25)
Lung Neoplasms - Pathology
(20)
Lung Cancer
(18)
Respiratory System
(16)
Adult
(15)
Immunotherapy
(15)
Lung Neoplasms - Genetics
(15)
Aged, 80 And Over
(14)
Neoplasm Staging
(14)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(13)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(13)
Chemotherapy
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Updated Analysis of KEYNOTE-024: Pembrolizumab Versus Platinum-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score of 50% or Greater

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non-Small-Cell Lung Cancer

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study

Small cell lung cancer: will recent progress lead to improved outcomes?

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial

Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline

Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study

Incidence of EGFR Exon 19 Deletions and L858R in Tumor Specimens From Men and Cigarette Smokers With Lung Adenocarcinomas

Efficacy and safety of treatments for advanced thymic carcinoma after failure of first-line platinum-based chemotherapy: A systematic literature review and meta-analysis

Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling

First-line pembrolizumab monotherapy for metastatic PD-L1-positive NSCLC: real-world analysis of time on treatment

Long-Term Real-World Outcomes of First-Line Pembrolizumab Monotherapy for Metastatic Non-Small Cell Lung Cancer With ≥50% Expression of Programmed Cell Death-Ligand 1

Reply to F. Liang

Phase II Trial of Temozolomide in Patients with Relapsed Sensitive or Refractory Small Cell Lung Cancer, with Assessment of Methylguanine-DNA Methyltransferase as a Potential Biomarker

Safety of pembrolizumab as adjuvant therapy in a pooled analysis of phase 3 clinical trials of melanoma, non–small cell lung cancer, and renal cell carcinoma

Kidney Tubular Toxicity of Maintenance Pemetrexed Therapy

Phase I/II Trial of Cetuximab and Erlotinib in Patients with Lung Adenocarcinoma and Acquired Resistance to Erlotinib

Molecular epidemiology study of programmed death ligand 1 and ligand 2 protein expression assessed by immunohistochemistry in extensive-stage small-cell lung cancer

Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology

Prevalence of BRCA1 and BRCA2 mutations in Ashkenazi Jewish families with breast and pancreatic cancer

Real-World Time on Treatment with First-Line Pembrolizumab Monotherapy for Advanced NSCLC with PD-L1 Expression ≥ 50%: 3-Year Follow-Up Data

Patterns of failure in limited-stage small cell lung cancer: Implications of TNM stage for prophylactic cranial irradiation

Bronchial and Thymic Carcinoid Tumors

Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC

Five-Year Outcomes With Pembrolizumab Versus Chemotherapy for Metastatic Non-Small-Cell Lung Cancer With PD-L1 Tumor Proportion Score ≥ 50

Suchergebnisse filtern